Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib or Nilutamide in mCRPC
NCT00918385Phase 2Terminated
- Sponsor
- Duke University
- Start
- May 2009
- Primary completion
- Feb 2012
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of dasatinib, nilutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Duke University. Started May 2009; status: terminated.
02
Drugs
dasatinibnilutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00918385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00918385.